Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism

Authors:

Abstract
No abstract available
Funding Information
  • Boehringer Ingelheim Pharma GmbH & Co. KG

This publication has 39 references indexed in Scilit: